ArticleBiochemical and biophysical research communications2025
β2-Adrenergic receptor regulates osteoblast differentiation and migration and C-terminal β-catenin phosphorylation.
Article in Biochemical and biophysical research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A Letter Matters: ADRB2 rs1042713 c.46A Modulates Anti-osteogenic Effect of Epinephrine in Human Mesenchymal Stem Cells.Stem cell reviews and reports · 2026Article
- m6A RNA modifications in neurosystem genes as early markers for osteoporosis with iron accumulation.Molecular biology reports · 2026Article
- Sympathetic regulation of bone homeostasis and remodeling: molecular mechanisms, pathophysiological roles, and therapeutic implications.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The sympathetic nervous system modulates bone mass in part by inhibiting bone formation through the osteoblastic β2-adrenergic receptor (β2AR), but understanding of the bone anabolic processes hindered by β2AR signaling is incomplete. Canonical Wnt signaling is anabolic in bone, promoting osteoblastic bone formation when the multifunctional β-catenin protein is unphosphorylated at N-terminal residues. In the present study, osteoblastic consequences of Wnt-independent β-catenin C-terminal phosphorylation downstream of β2AR activation were investigated. Treatment with the β-adrenergic agonist isoproterenol (ISO) decreased mineralized nodule formation in differentiating cultures of MC3T3 pre-osteoblasts and BMSCs from WT mice, but not BMSCs from β2AR deficient mice. After treatment with ISO or the β2AR agonist salbutamol there was increased phosphorylation of β-catenin at serine residues 552 and 675, whereas phosphorylation at canonical Wnt-dependent N-terminal sites was unaffected. These C-terminal serine phosphorylation events were inhibited by pre-treatment with β-adrenergic antagonist propranolol or PKA inhibitor H89, indicating that β-catenin phosphorylation downstream of β2AR occurs via G-protein coupled signaling. These phosphorylation events were also dependent on PAK4 kinase activation. Also, co-immunoprecipitation studies suggested enhanced interaction of β-catenin protein phosphorylated at Ser552 with cadherin 11. Finally, β-adrenergic stimulation increased osteoblast attachment and reduced migration, and transfection studies indicated a requirement for serine phosphorylated β-catenin in these effects. These data suggest that increased interaction between cadherin and the C-terminal serine-phosphorylated β-catenin species may contribute to β2AR delay of osteoblast migration. Thus, β-catenin is a novel downstream effector of β2AR signaling and may link β2AR activity to changes in osteoblast cell structure and function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.